MARKET

PGEN

PGEN

Precigen Inc
NASDAQ
1.885
-0.045
-2.33%
Opening 13:24 02/07 EST
OPEN
1.940
PREV CLOSE
1.930
HIGH
2.009
LOW
1.870
VOLUME
1.52M
TURNOVER
1.36M
52 WEEK HIGH
2.900
52 WEEK LOW
1.120
MARKET CAP
473.15M
P/E (TTM)
-4.5631
1D
5D
1M
3M
1Y
5Y
$20 Million Bet On Precigen? Check Out These 4 Penny Stocks Insiders Are Buying
Benzinga · 6d ago
Insider Buy: Precigen
Insider Buy: Precigen
MT Newswires · 01/31 16:18
Precigen: Will Financing Issues Forever Cloud The Promise?
Seeking Alpha · 01/31 12:34
Cantor Fitzgerald Maintains Overweight on Precigen, Raises Price Target to $10
Benzinga · 01/30 13:37
--Cantor Fitzgerald Adjusts Price Target on Precigen to $10 From $7, Maintains Overweight Rating
--Cantor Fitzgerald Adjusts Price Target on Precigen to $10 From $7, Maintains Overweight Rating
MT Newswires · 01/30 10:45
Precigen Closes $75 Million Common Stock Offering
Precigen Closes $75 Million Common Stock Offering
MT Newswires · 01/30 04:39
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring, But Not Yet Talking About
Benzinga · 01/26 20:56
Health Rounds: Stroke prediction tools failing Black patients
Reuters · 01/26 16:52
More
About PGEN
Precigen, Inc. (Precigen) is a synthetic biology company that focuses on its discovery and clinical-stage activities to advance gene and cellular therapies to target immuno-oncology, autoimmune disorders, and infectious diseases. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. The Company’s lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. The Company also completed a Phase I study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. It also has a robust pipeline of preclinical programs.

Webull offers kinds of Precigen Inc stock information, including NASDAQ:PGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PGEN stock methods without spending real money on the virtual paper trading platform.